Rallybio Corp

RLYB

Company Profile

  • Business description

    Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

  • Contact

    234 Church Street
    Suite 1020
    New HavenCT06510
    USA

    T: +1 203 859-3820

    https://www.rallybio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    20

Stocks News & Analysis

stocks

Oracle shares are up 87% in 2025. Is it a buy?

Oracle’s cloud database business is riding the AI wave.
stocks

Bumper crop to benefit ASX listed share

We raise our earnings forecast 11% for next year.
stocks

Is there a long-term buying opportunity in luxury stocks?

Our analysts think the recent wobble in revenue growth is cyclical, not structural.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,137.8014.900.16%
CAC 407,900.7570.640.90%
DAX 4023,691.89164.840.70%
Dow JONES (US)46,381.5466.270.14%
FTSE 1009,261.0134.330.37%
HKSE26,159.12185.02-0.70%
NASDAQ22,788.98157.500.70%
Nikkei 22545,493.66447.850.99%
NZX 50 Index13,136.545.00-0.04%
S&P 5006,693.7529.390.44%
S&P/ASX 2008,845.9014.300.16%
SSE Composite Index3,821.836.74-0.18%

Market Movers